Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Flaherty

Showing results (41-50 of 121) with videos related to

Pageof 13
Sort By:
Cancer|March 27, 2001
Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trialsJ M Unger, L E Flaherty, P Y Liu, et al.
American Journal of Clinical Oncology|December 18, 1998
Metastatic melanoma from intraocular primary tumors: the Southwest Oncology Group experience in phase II advanced melanoma clinical trialsL E Flaherty, J M Unger, P Y Liu, et al.
American Journal of Diseases of Children (1960)|June 1, 1989
Umbilical cord circumference at birthD Patel, M Dawson, P Kalyanam, et al.
Cancer|July 1, 1994
Oral etoposide in the treatment of hormone-refractory prostate cancerM H Hussain, K J Pienta, B G Redman, et al.
The American Naturalist|August 19, 2008
Stage-structured infection transmission and a spatial epidemic: a model for Lyme diseaseThomas Caraco, Stephan Glavanakov, Gang Chen, et al.
Molecular Metabolism|November 1, 2019
Conditional deletion of melanin-concentrating hormone receptor 1 from GABAergic neurons increases locomotor activityMelissa J Chee, Alex J Hebert, Nadege Briançon, et al.
AJR. American Journal of Roentgenology|February 1, 1990
Scintigraphic findings in patients with shoulder pain caused by interleukin-2N W Baron, L P Davis, L E Flaherty, et al.
Cancer|August 5, 2000
Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinomaC Trivedi, B Redman, L E Flaherty, et al.
Advance for Nurse Practitioners|October 29, 2002
Providing optimal hands-on experience. A guide for clinical preceptorsV Fay, K S Feldt, S A Greenberg, et al.
Urology|August 11, 1998
A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancerD C Smith, B G Redman, L E Flaherty, et al.
Pageof 13

Showing results (41-50 of 121) with videos related to

Sort By:
Pageof 13
Cancer|March 27, 2001
Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trialsJ M Unger, L E Flaherty, P Y Liu, et al.
American Journal of Clinical Oncology|December 18, 1998
Metastatic melanoma from intraocular primary tumors: the Southwest Oncology Group experience in phase II advanced melanoma clinical trialsL E Flaherty, J M Unger, P Y Liu, et al.
American Journal of Diseases of Children (1960)|June 1, 1989
Umbilical cord circumference at birthD Patel, M Dawson, P Kalyanam, et al.
Cancer|July 1, 1994
Oral etoposide in the treatment of hormone-refractory prostate cancerM H Hussain, K J Pienta, B G Redman, et al.
The American Naturalist|August 19, 2008
Stage-structured infection transmission and a spatial epidemic: a model for Lyme diseaseThomas Caraco, Stephan Glavanakov, Gang Chen, et al.
Molecular Metabolism|November 1, 2019
Conditional deletion of melanin-concentrating hormone receptor 1 from GABAergic neurons increases locomotor activityMelissa J Chee, Alex J Hebert, Nadege Briançon, et al.
AJR. American Journal of Roentgenology|February 1, 1990
Scintigraphic findings in patients with shoulder pain caused by interleukin-2N W Baron, L P Davis, L E Flaherty, et al.
Cancer|August 5, 2000
Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinomaC Trivedi, B Redman, L E Flaherty, et al.
Advance for Nurse Practitioners|October 29, 2002
Providing optimal hands-on experience. A guide for clinical preceptorsV Fay, K S Feldt, S A Greenberg, et al.
Urology|August 11, 1998
A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancerD C Smith, B G Redman, L E Flaherty, et al.
Pageof 13